As showdown with activist nears, Illumina’s CEO defends the company’s $7.1B purchase of Grail

Jared Whitlock

Features Editor

Two years after Illumina bought the cancer testing company Grail, the DNA sequencing giant remains beleaguered by antitrust issues and is weeks away from the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As showdown with activist nears, Illumina’s CEO defends the company’s $7.1B purchase of Grail

Jared Whitlock

Features Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As show­down with ac­tivist nears, Il­lu­mi­na’s CEO de­fends the com­pa­ny’s $7.1B pur­chase of Grail

Features Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As showdown with activist nears, Illumina’s CEO defends the company’s $7.1B purchase of Grail